Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Exagen Announces Launch of Novel Biomarker PC4d Associated with Thrombosis in Lupus | ||
By: Nasdaq / GlobeNewswire - 12 Oct 2018 | Back to overview list |
|
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests ALBUQUERQUE, NM and SAN DIEGO, CA, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Exagen Diagnostics, a leader in autoimmune life sciences, announced today that it will be updating the popular AVISE® SLE Monitor test to include levels of platelet-bound C4d (PC4d). Exagen will be the only laboratory offering this unique biomarker which is significantly associated with thrombosis in patients with systemic lupus erythematosus (SLE).
================================================================== To learn more about Exagen Diagnostics, please visit www.Exagen.com. About Exagen’s AVISE laboratory tests AVISE Connective Tissue Disease (CTD) is a diagnostic test which supports care providers with an accurate assessment of critical biomarkers in patients suspected of SLE or rheumatic conditions with similar symptoms. AVISE Lupus uniquely incorporates biologically-relevant CB-CAPs (Cell-Bound Complement Activation Products) into a proprietary algorithm that yields an index value which is associated with the likelihood for the presence of SLE. This amounts to a convenient test for the differential diagnosis of SLE with demonstrated performance of 80% sensitivity and 86% specificity. CB-CAPs provide 22% higher sensitivity for SLE than standard complement measures C3 or C4 alone. The AVISE Lupus test offers 48% greater sensitivity than traditional anti-dsDNA alone. AVISE SLE Monitor is a combination of five advanced tests and provides important data to assist physicians anytime they assess the status of a patient with SLE. This test employs erythrocyte bound C4d (EC4d) along with other key markers which have demonstrated significant correlation to SLE disease activity. This is the test that will soon feature the addition of the novel PC4d assay. AVISE SLE Monitor gives the treating care provider an accurate glimpse into the serologic measures of disease activity allowing for a more complete picture of how well a patient’s condition is being managed. About Exagen Exagen is a commercial stage life sciences company that is patient focused, and discovery driven. Exagen serves patients and healthcare providers across the U.S. in the diagnosis, prognosis, and management of lupus, rheumatoid arthritis, and other autoimmune conditions. By leveraging our patented and validated Cell-bound Complement Activation Products (CB-CAPs) technology we can help get to the real cause of a patient’s symptoms and guide their journey to improved health. For more information, visit www.exagen.com or follow us on Facebook, Twitter, YouTube, LinkedIn, or Instagram. Exagen, AVISE, and the Exagen and AVISE logos are registered trademarks of Exagen Diagnostics Inc. Key Words: Lupus, Lupus Diagnosis, #LupusLabFacts, Autoimmune, Laboratory, AVISE CTD, AVISE, #WTDay18, #KnowThrombosis, #KeepLifeFlowing, #WorldThrombosisDay, #ACR18
Contact: Brian McEvilly Exagen Diagnostics, Inc. bmcevilly@exagen.com 760-560-1506 Attachment CONTACT: Brian McEvilly Exagen Diagnostics, Inc. 858-736-5517 bmcevilly@exagen.com |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |